Vanguard Group’s Alzamend Neuro ALZN Stock Holding History

Vanguard Group’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$39.3K	Hold	21,620	–	–	﹤0.01%	4269
2025 Q3	$51.5K	Buy	+21,620	New	+$56.1K	﹤0.01%	4296
2024 Q3	–	Sell	-873	Closed	-$31K	–	4351
2024 Q2	$31K	Hold	873	–	–	﹤0.01%	4330
2024 Q1	$78.5K	Hold	873	–	–	﹤0.01%	4263
2023 Q4	$69.9K	Sell	873 -635	-42%	-$104K	﹤0.01%	4343
2023 Q3	$482K	Sell	1,508 -1	-0.1%	-$478	﹤0.01%	4061
2023 Q2	$1.04M	Hold	1,509	–	–	﹤0.01%	3885
2023 Q1	$866K	Sell	1,509 -412	-21%	-$310K	﹤0.01%	3965
2022 Q4	$1.46M	Sell	1,921 -1,113	-37%	-$1.61M	﹤0.01%	3782
2022 Q3	$4.87M	Buy	3,034 +2,989	+6,642%	+$4.11M	﹤0.01%	3342
2022 Q2	$53K	Buy	+45	New	+$58.3K	﹤0.01%	4581

Other funds holding ALZN

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group's ALZN Position: Q4 2025 in Review

Vanguard Group held its Alzamend Neuro (ALZN) position steady in Q4 2025 at 21,620 shares worth $39.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4269.

Vanguard Group first reported a position in ALZN in Q2 2022 and has held it in 11 quarters since. The position peaked at $4.87M in Q3 2022. 13 funds tracked by Wall St. Rank hold ALZN as of Q4 2025.

Vanguard Group held 21,620 shares of Alzamend Neuro worth $39.3K as of Q4 2025.
Vanguard Group left its Alzamend Neuro share count unchanged in Q4 2025.
Alzamend Neuro made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4269 holding.
Vanguard Group first reported a position in Alzamend Neuro in Q2 2022 and has held it in 11 quarters since.
Vanguard Group's Alzamend Neuro position peaked at $4.87M in Q3 2022.
13 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.